Stock News

Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment

Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma

Merck's (NYSE:MRK) investors will be pleased with their notable 90% return over the last three years

Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know

Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy

Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent

Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers

Q1 2024 OPKO Health Inc Earnings Call

Merck to Participate in the Bank of America Securities 2024 Healthcare Conference

Gossamer sells rights to drug it hopes can rival a new Merck therapy

Merck First Quarter 2024 Earnings: Beats Expectations

Here's Why Merck (MRK) is a Strong Momentum Stock

Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration

15 Best Places to Retire in Florida That You’ve Never Heard Of

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

3 Pharma Stocks With the Potential to Make You an Overnight Millionaire

Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript

Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults

Merck & Co., Inc. (NYSE:MRK) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Merck (MRK) Q1 2024 Earnings Call Transcript

As seen on...